About Sensimed
Sensimed is a company based in Lausanne (Switzerland) founded in 2003 was acquired by SEED in December 2019. Sensimed has raised $41.82 million across 4 funding rounds from investors including Seed, Vertex Ventures and Wellington Partners Venture Capital. Sensimed offers products and services including SENSIMED Triggerfish. Sensimed operates in a competitive market with competitors including Ivantis, Transcend Medical, Alievio, i-Optics and Implandata, among others.
- Headquarter Lausanne, Switzerland
-
Sectors
TechnologyHealthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Sensimed S.A.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Sensimed
Sensimed offers a comprehensive portfolio of products and services, including SENSIMED Triggerfish.
Smart contact lens for 24-hour eye pressure monitoring in glaucoma.
Funding Insights of Sensimed
Sensimed has successfully raised a total of $41.82M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $8.27 million completed in July 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Sensimed
Sensimed has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Seed, Vertex Ventures and Wellington Partners Venture Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in early-stage healthcare startups.
|
Locked | Locked | Locked | |
|
Growth capital is provided to mature MedTech companies by Agate.
|
Locked | Locked | Locked | |
|
A family office service is provided by Sandoz Family Foundation.
|
Locked | Locked | Locked |
Investor details for Sensimed
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sensimed
Investment portfolio details for Sensimed
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Sensimed
Detailed financials for Sensimed
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sensimed Comparisons
Peer comparison for Sensimed
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sensimed
Sensimed operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ivantis, Transcend Medical, Alievio, i-Optics and Implandata, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Implantable device to relieve intraocular pressure in open angle glaucoma
|
|
| Locked | Locked | Locked |
Minimally invasive glaucoma stents are developed to enhance aqueous outflow.
|
|
| Locked | Locked | Locked |
A noninvasive glaucoma device is developed to drain aqueous humor.
|
|
| Locked | Locked | Locked |
i-Optics specializes in providing advanced retina and cornea imaging systems for medical professionals.
|
|
| Locked | Locked | Locked |
Intraocular pressure is monitored continuously via an implantable microsensor.
|
Detailed competitors of Sensimed
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sensimed
Complete news archive for Sensimed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sensimed
Sensimed was founded in 2003 and raised its 1st funding round 4 years after it was founded.
Sensimed is headquartered in Lausanne, Switzerland. It is registered at Lausanne, Vaud, Switzerland.
Sensimed is a funded company, having raised a total of $41.82M across 4 funding rounds to date.
Sensimed was founded in 2003 in Lausanne, Switzerland, and operates in the medical device sector focused on ophthalmology. A non-invasive soft contact lens solution for glaucoma management is provided by the company. Continuous ocular dimensional changes are recorded automatically over a full day. The platform has received CE and FDA approvals, supporting clinical monitoring needs in eye health.
Sensimed's top competitors include Ivantis, Transcend Medical and Alievio.
Sensimed offers SENSIMED Triggerfish.
Sensimed has 8 investors. Key investors include Seed, Vertex Ventures, Wellington Partners Venture Capital, Agate Medical Investments, and Renaissance.